MADRIGAL PHARMACEUTICALS, INC. (MDGL) Form 8-K — Aug 12, 2026

$MDGLForm 8-KItems 5.02, 7.01, 9.01Filed Aug 12, 2026, 8:18 AM ET0001628280-26-055962Original filing

Madrigal Pharmaceuticals expanded its board from eight to nine members and elected John C. Reed, M.D., Ph.D., as a Class II director effective August 11, 2026, with a term expiring at the 2027 annual meeting of stockholders. Dr. Reed currently leads Innovative Medicine Research & Development at Johnson & Johnson and previously held executive R&D roles at Sanofi and Roche, bringing a track record that includes more than 900 scientific publications and more than 130 patents.

Key figures

Board Size After: 9
Board Size Before: 8
Equity Grant Split: 50% nonqualified stock options / 50% restricted stock units under the 2026 Stock Plan
Committee Annual Retainer Usd: 10000
Initial Equity Grant Value Usd: 675000
Director Annual Cash Retainer Usd: 50000

Price after filing

1 day: -5.4%7 days: +0.7%30 days: -0.3%

Close on the filing date to close N calendar days later (from $536.20). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.